A randomized, multi-center, open-label, parallel group feasibility study to determine the safety and efficacy of the rationally engineered heparin M118 vs. unfractionated heparin (UFH) in subjects with stable coronary artery disease undergoing percutaneous coronary intervention (PCI) And A Pharmacokinetic, Pharmacodynamic and Heparin Antibody Substudy

Trial Profile

A randomized, multi-center, open-label, parallel group feasibility study to determine the safety and efficacy of the rationally engineered heparin M118 vs. unfractionated heparin (UFH) in subjects with stable coronary artery disease undergoing percutaneous coronary intervention (PCI) And A Pharmacokinetic, Pharmacodynamic and Heparin Antibody Substudy

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Apr 2013

At a glance

  • Drugs Adomiparin; Heparin
  • Indications Cardiovascular disorders; Coronary artery disease; Embolism and thrombosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EMINENCE
  • Sponsors Momenta Pharmaceuticals
  • Most Recent Events

    • 07 Apr 2010 Results were published in Circulation, according to a Momenta Pharmaceuticals media release.
    • 02 Oct 2009 Actual patient number (503) added as reported by ClinicalTrials.gov.
    • 02 Oct 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top